Cancer biotech Tango Therapeutics picks a SPAC as its IPO dance partner April 14, 2021 Auto Bot BioPharma, biopharma nl, biotech IPO, Cambridge, cancer drugs, Massachusetts, Pharma 0 Tango Therapeutics’ SPAC merger will infuse the biotech with $353 million to fund clinical trials for its cancer drugs based on synthetic lethality. Tango’s lead program is on track to reach the clinic next year.